Open AccessMyostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance
Author(s) -
Busquets Sílvia,
Toledo Míriam,
Orpí Marcel,
Massa David,
Porta Maria,
Capdevila Eva,
Padilla Núria,
Frailis Valentina,
López-Soriano Francisco J.,
Han H. Q.,
Argilés Josep M.
Publication year - 2012
Publication title -
journal of cachexia, sarcopenia and muscle
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.803
H-Index - 66
eISSN - 2190-6009
pISSN - 2190-5991
DOI - 10.1007/s13539-011-0049-z
Subject(s) - myostatin , wasting , lewis lung carcinoma , antagonism , medicine , muscle hypertrophy , cancer , receptor , metastasis
Background Cachexia is a multiorganic syndrome associated with cancer, characterized by body weight loss, muscle and adipose tissue wasting and inflammation. Methods The aim of this investigation was to examine the effect of the soluble receptor antagonist of myostatin (sActRIIB) in cachectic tumor‐bearing animals analyzing changes in muscle proteolysis and in quality of life. Results Administration of sActRIIB resulted in an improvement in body and muscle weights. Administration of the soluble receptor antagonist of myostatin also resulted in an improvement in the muscle force. Conclusions These results suggest that blocking myostatin pathway could be a promising therapeutic strategy for the treatment of cancer cachexia.